 Cullen Dutmer
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 5 | 2022 | 66 | 1.570 |
Why?
| | Urban Population | 3 | 2022 | 401 | 0.990 |
Why?
| | Hypersensitivity | 2 | 2023 | 256 | 0.800 |
Why?
| | Anemia, Hemolytic, Autoimmune | 2 | 2024 | 13 | 0.750 |
Why?
| | Asthma | 6 | 2022 | 2051 | 0.740 |
Why?
| | Biological Products | 1 | 2023 | 171 | 0.690 |
Why?
| | Environmental Exposure | 2 | 2018 | 377 | 0.500 |
Why?
| | Herpes Zoster | 2 | 2015 | 333 | 0.480 |
Why?
| | Viral Vaccines | 1 | 2015 | 89 | 0.480 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 380 | 0.410 |
Why?
| | Poverty | 1 | 2016 | 443 | 0.410 |
Why?
| | Stress, Psychological | 1 | 2018 | 946 | 0.350 |
Why?
| | Allergy and Immunology | 2 | 2020 | 53 | 0.330 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 342 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 334 | 0.240 |
Why?
| | Pandemics | 3 | 2020 | 1321 | 0.220 |
Why?
| | Biological Factors | 1 | 2023 | 36 | 0.210 |
Why?
| | Haploinsufficiency | 2 | 2021 | 44 | 0.210 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1747 | 0.210 |
Why?
| | CTLA-4 Antigen | 2 | 2021 | 78 | 0.210 |
Why?
| | Immune System Diseases | 1 | 2022 | 34 | 0.210 |
Why?
| | Pulmonary Eosinophilia | 1 | 2022 | 26 | 0.200 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2021 | 26 | 0.190 |
Why?
| | Ikaros Transcription Factor | 1 | 2021 | 18 | 0.190 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 57 | 0.190 |
Why?
| | Prevalence | 2 | 2018 | 2255 | 0.180 |
Why?
| | Vasculitis | 1 | 2021 | 71 | 0.180 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 15 | 0.180 |
Why?
| | Growth Disorders | 1 | 2020 | 78 | 0.180 |
Why?
| | Microcephaly | 1 | 2020 | 52 | 0.170 |
Why?
| | Humans | 22 | 2024 | 115039 | 0.170 |
Why?
| | Eczema | 1 | 2020 | 82 | 0.170 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 20 | 0.170 |
Why?
| | Oligonucleotides | 1 | 2020 | 138 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2020 | 129 | 0.160 |
Why?
| | Histone Deacetylases | 1 | 2020 | 196 | 0.160 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 125 | 0.160 |
Why?
| | Colitis | 1 | 2021 | 226 | 0.160 |
Why?
| | Genetic Therapy | 1 | 2020 | 258 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 211 | 0.150 |
Why?
| | Rhinovirus | 1 | 2018 | 41 | 0.150 |
Why?
| | Cities | 1 | 2018 | 81 | 0.150 |
Why?
| | Mutation | 4 | 2022 | 3350 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2020 | 368 | 0.150 |
Why?
| | Allergens | 2 | 2018 | 417 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2021 | 350 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 288 | 0.140 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 524 | 0.140 |
Why?
| | Phenotype | 3 | 2020 | 2815 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2021 | 772 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 383 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1355 | 0.130 |
Why?
| | Omalizumab | 1 | 2016 | 46 | 0.130 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 19 | 0.130 |
Why?
| | Homeodomain Proteins | 1 | 2019 | 464 | 0.130 |
Why?
| | Disease Management | 2 | 2016 | 563 | 0.130 |
Why?
| | Schools | 1 | 2018 | 400 | 0.120 |
Why?
| | Exanthema | 1 | 2015 | 76 | 0.120 |
Why?
| | Pedigree | 1 | 2015 | 467 | 0.120 |
Why?
| | Disease Progression | 2 | 2018 | 2389 | 0.110 |
Why?
| | Brain Diseases | 1 | 2015 | 127 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2551 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 835 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 441 | 0.100 |
Why?
| | Child | 6 | 2022 | 18407 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2108 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 499 | 0.100 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1042 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2015 | 593 | 0.090 |
Why?
| | Autoimmunity | 3 | 2022 | 818 | 0.090 |
Why?
| | DNA-Binding Proteins | 1 | 2015 | 1318 | 0.080 |
Why?
| | Cells, Cultured | 1 | 2015 | 3896 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 665 | 0.070 |
Why?
| | Risk Factors | 2 | 2017 | 8642 | 0.070 |
Why?
| | United States | 2 | 2022 | 12224 | 0.070 |
Why?
| | Infant | 4 | 2020 | 7945 | 0.070 |
Why?
| | Adolescent | 3 | 2020 | 17862 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2022 | 2191 | 0.060 |
Why?
| | Female | 6 | 2021 | 59611 | 0.050 |
Why?
| | Gain of Function Mutation | 1 | 2022 | 31 | 0.050 |
Why?
| | Animals | 3 | 2021 | 31867 | 0.050 |
Why?
| | Telemedicine | 2 | 2020 | 665 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2021 | 272 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 174 | 0.050 |
Why?
| | Facies | 1 | 2020 | 21 | 0.050 |
Why?
| | Lymphocytes | 1 | 2022 | 334 | 0.050 |
Why?
| | Granuloma | 1 | 2021 | 85 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 9 | 0.040 |
Why?
| | Prednisolone | 1 | 2020 | 76 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 156 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 103 | 0.040 |
Why?
| | Exome | 1 | 2020 | 201 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Ipilimumab | 1 | 2019 | 28 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 75 | 0.040 |
Why?
| | Eosinophils | 1 | 2021 | 281 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 188 | 0.040 |
Why?
| | Genome, Human | 1 | 2020 | 351 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2019 | 276 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 224 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2019 | 415 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 182 | 0.040 |
Why?
| | Climate | 1 | 2017 | 85 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 340 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 370 | 0.030 |
Why?
| | Signal Transduction | 2 | 2019 | 4525 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 122 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 9093 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 641 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 394 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 535 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 9122 | 0.030 |
Why?
| | Virus Diseases | 1 | 2017 | 196 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 170 | 0.030 |
Why?
| | Male | 4 | 2021 | 55730 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 651 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2015 | 285 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1379 | 0.030 |
Why?
| | Immunization | 1 | 2016 | 400 | 0.030 |
Why?
| | Precision Medicine | 1 | 2017 | 340 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 520 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1127 | 0.030 |
Why?
| | Research | 1 | 2016 | 395 | 0.030 |
Why?
| | Melanoma | 1 | 2019 | 622 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4904 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1457 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4718 | 0.030 |
Why?
| | Middle Aged | 2 | 2021 | 26827 | 0.020 |
Why?
| | Microbiota | 1 | 2016 | 648 | 0.020 |
Why?
| | Adult | 2 | 2021 | 30655 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2485 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3419 | 0.020 |
Why?
| | Mice | 1 | 2021 | 14927 | 0.020 |
Why?
| | Lung | 1 | 2017 | 3595 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 10498 | 0.010 |
Why?
|
|
Dutmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|